These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34414233)

  • 1. PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer.
    Li L; Xu F; Xie P; Yuan L; Zhou M
    Biomed Res Int; 2021; 2021():3301402. PubMed ID: 34414233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
    Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
    Front Immunol; 2022; 13():991091. PubMed ID: 36248841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
    Sen M; Kindsfather A; Danilova L; Zhang F; Colombo R; LaPorte MG; Kurland BF; Huryn DM; Wipf P; Herman JG
    Epigenetics; 2020; 15(6-7):604-617. PubMed ID: 31595832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
    Peyser ND; Freilino M; Wang L; Zeng Y; Li H; Johnson DE; Grandis JR
    Oncogene; 2016 Mar; 35(9):1163-9. PubMed ID: 25982282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
    Zhao Y; Scott A; Zhang P; Hao Y; Feng X; Somasundaram S; Khalil AM; Willis J; Wang Z
    Oncotarget; 2017 Jul; 8(30):48782-48793. PubMed ID: 27447856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
    Yao Y; Shao J; Wu J; Zhang Q; Wang J; Xiao D; Huang F
    Cell Physiol Biochem; 2015; 36(1):306-14. PubMed ID: 25967969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
    Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
    Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
    Si X; Liu Y; Lv J; Ding H; Zhang XA; Shao L; Yang N; Cheng H; Sun L; Zhu D; Yang Y; Li A; Han X; Sun Y
    Oncotarget; 2016 Apr; 7(15):20966-80. PubMed ID: 26980709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer.
    Laczmanska I; Karpinski P; Kozlowska J; Bebenek M; Ramsey D; Sedziak T; Ziolkowski P; Sasiadek MM
    Pathol Res Pract; 2014 Dec; 210(12):893-6. PubMed ID: 25169130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-scale analysis of
    Croes L; Beyens M; Fransen E; Ibrahim J; Vanden Berghe W; Suls A; Peeters M; Pauwels P; Van Camp G; Op de Beeck K
    Clin Epigenetics; 2018; 10():51. PubMed ID: 29682089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
    Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
    BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and Prognostic Value of the TauProtein in Breast Cancer.
    Bonneau C; Gurard-Levin ZA; Andre F; Pusztai L; Rouzier R
    Anticancer Res; 2015 Oct; 35(10):5179-84. PubMed ID: 26408675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.